**Publications**

* **Frontini R**. Wie „nützlich“ sind Orphan Drugs? Auch Arzneimittel für seltene Krankheiten müssen ihre klinische Effektivität zeigen. Deutsche Apotheker Zeitung 2022;162(12):30-32
* **Frontini R**. Wachsame Augen für sichere Arzneimittel. Pharmakovigilanz ist auch eine europäische Aufgabe. Uni-DAZ 2022;1:36-37
* Kuruc-Poje D , Kifer D, Huys I, Miranda J, Jenzer H, Miljković N, Hoppe-Tichy T, Bochniarz M, **Frontini R**, Schwartz DG, Vujić-Aleksić V, Nežić L, Rinaki E, Tzimis L, Green K, Jovanić J, Carić B, Mandić D, Vilić K, Bochenek T, Bačić Vrca V, Marušić S. Patients perspectives on drug shortages in six European hospital settings – a cross sectional study. BMC Health Services Research 2021; 21: 689. https://doi.org/10.1186/s12913-021-06721-9.
* **Frontini R.** Das Dilemma der SARS-CoV-2-Impfstoffbeurteilung. Deutsche Apotheker Zeitung 2021;161(15):38-39
* **Frontini R**. Europäische Behörde unter Zeitdruck. Uni-DAZ 2021;1:28-30
* Neininger MP, Buchholz P, **Frontini R**, Kiess W, Siekmeyer W, Bertsche A, Siekmeyer M, Bertsche T. Incompatible intravenous drug combinations and respective physician and nurse knowledge: a study in routine paediatric intensive care. Eur J Hosp Pharm. 2019;26(4):214-217.
* Lingor P, Weber M, Camu W, Friede T, Hilgers R, Leha A, Neuwirth C, Günther R, Benatar M, Kuzma-Kozakiewicz M, Bidner H, Blankenstein C, **Frontini R**, Ludolph A, Koch JC. ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis. Front Neurol. 2019;10:293.
* Jansen-Winkeln B, Thieme R, Haase L, Niebisch S, Pommer C, Lyros O, Zimmer J, Lordick F, Remane Y, **Frontini R**, Gockel I. Perioperative safety of intraperitoneal aerosol chemotherapy : Analysis of our first 111 pressurized intraperitoneal aerosol chemotherapy (PIPAC) procedures. Chirurg. 2019;90(2):137-145.
* West LM, Vetter-Kerkhoff C, Miljkovic N, **Frontini R**. Is there a need for a hospital pharmacy common training framework? Review of the literature on the impact of educational interventions on health outcome. Eur J Hosp Pharm. 2018;25(1):6-9.
* Pfeifer C, Noll S, Gerecke H, Fassauer G, Jira T, Remane Y, Vogel J, **Frontini R**, Reinhardt R. A stability study of amphotericin B, colistin and tobramycin in a hydrophilic suspension commonly used for selective decontamination of the digestive tract by HPLC and in vitro potency measurements. Eur J Hosp Pharm. 2017;24(4):235-241.
* Bertsche T, Schiek S, Neininger MP, **Frontini R**. Die Arzneimitteltherapie der Patienten sicherer machen Interdisziplinäre Konzepte am Leipziger Zentrum für Arzneimittelsicherheit. Med Monatsschr Pharm. 2017;40(4):171-3.
* Zimmer J, Hartl S, Standfuß K, Möhn T, Bertsche A, **Frontini R**, Neininger MP, Bertsche T. Handling of hazardous drugs - Effect of an innovative teaching session for nursing students. Nurse Educ Today. 2017;49:72-78.
* **Frontini R**. Falsified Medicines Directive: Are We Heading in the Right Direction? Medicine Access @ Point of Care. 2017;1, e55-e57
* Schiek S, Moritz K, Seichter SJ, Ghanem M, von Salis-Soglio G, **Frontini R**, Bertsche T. Standardising analgesic administration for nurses: a prospective intervention study. Int J Clin Pharm. 2016;38(6):1497-1504.
* Cobaugh DJ, Chen TF, **Frontini R**, Al Hail M, Hattingh J, Kurosawa N, Savio E. Advancing responsible use of medicines globally: The revised Basel Statements.American Journal of Health-System Pharmacy 2016;73 (14):1027-1028.
* Kaune A, Schumacher PM, Hoppe SC, Syrbe S, Bernhard MK, **Frontini R**, Merkenschlager A, Kiess W, Neininger MP, Bertsche A, Bertsche T. Administration of anticonvulsive rescue medication in children-discrepancies between parents' self-reports and limited practical performance. Eur J Pediatr. 2016;175(9):1139-1146.
* **Frontini R**. In the shade of old pines. Am J Health Syst Pharm. 2016;73(13):991-5.
* Schiek S, Ghanem M, **Frontini R**, Hertel G, von Salis-Soglio G, Bertsche T. Pain assessment in routine care : A prospective observational study in an orthopedic unit. Schmerz. 2016;30(3):257-65.
* Zimmer J, Remane Y, **Frontini R**, Bertsche T. Herstellung applikationsfertiger oraler fester Zytostatika-Zubereitungen, Onkologische Pharmazie 2016; 18(2): 24-28.
* Zimmer J, Niemann D, Seltmann K, Fischer L, Christiansen H, **Frontini R**, Kiess W, Neininger MP, Bertsche A, Bertsche T. Managing of oral medicines in paediatric oncology: can a handbook and a pharmaceutical counselling intervention for patients and their parents prevent knowledge deficits? A pilot study. Eur J Hosp Pharm. 2016;23(2):100-105.
* **Frontini R**. Warum der p-Wert uns nur in die Irre führt- Oder warum Zahlen nicht immer ein guter Beweis sind. Krankenhauspharmazie 2015;36:381–3
* Neininger MP, Ullmann M, Dahse AJ, Syrbe S, Bernhard MK, **Frontini R**, Kiess W, Merkenschlager A, Thome U, Bertsche T, Bertsche A. Use of Levetiracetam in Neonates in Clinical Practice: A Retrospective Study at a German University Hospital. Neuropediatrics. 2015;46(5):329-34.
* Schiek S, Hildebrand C, Ranft D, Dürrbeck A, Ghanem M, von Salis-Soglio G, **Frontini R**, Bertsche T. A cohort study investigating medication management by pharmacists to prevent drug-related problems in pain therapy, Eur J Hosp Pharm 2015; 22:156-160.
* Schubert S, Neininger MP, Smers S, Winter A, **Frontini R**, Bertsche A, Bertsche T. Electronic drug prescription - auto pilot for drug therapy? Med Monatsschr Pharm. 2015;38(6):224-30.
* Pfeifer C, Fassauer G, Gerecke H, Jira T, Remane Y, **Frontini R**, Byrne J, Reinhardt R. Purity determination of amphotericin B, colistin sulfate and tobramycin sulfate in a hydrophilic suspension by HPLC. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 ;990:7-14.
* Bertsche T, Lindner S, Damm M, **Frontini R**, Exner C, Himmerich H. An interdisciplinary concept to optimize patient safety-a pilot study. Psychiatr Prax. 2015;42(4):216-20.
* Schnoor J, Rogalski C, **Frontini R**, Engelmann N, Heyde CE. Case report of a medication error by look-alike packaging: a classic surrogate marker of an unsafe system. Patient Saf Surg. 2015;9:12.
* Neininger MP, Kaune A, Bertsche A, Rink J, Musiol J, **Frontini R**, Prenzel F, Kiess W, Bertsche T. How to improve prescription of inhaled salbutamol by providing standardised feedback on administration: a controlled intervention pilot study with follow-up. BMC Health Serv Res. 2015;15:40.
* Bertsche A, Neininger MP, Dahse AJ, Syrbe S, Bernhard MK, **Frontini R**, Kiess W, Bertsche T, Merkenschlager A. Initial anticonvulsant monotherapy in routine care of children and adolescents: levetiracetam fails more frequently than valproate and oxcarbazepine due to a lack of effectiveness. Eur J Pediatr. 2014;173(1):87-92.
* **Frontini R**. The statements: a reflection on the results. Eur J Hosp Pharm 2014;21(5); 256-258.
* Preece D, Holme K, **Frontini R**, Tromp D, Price R. Admission into primary care: are we doing enough? Eur J Hosp Pharm. 2014;21: 79-83.

* **Frontini R**, Kubica U, Burjanko S, Bödeker H, Bertsche T. Leitlinienkonformität in der Antibiotikatherapie, Krankenhauspharmazie 2014;35 (3): 67–71.
* Bertsche A, Dahse AJ, Neininger MP, Bernhard MK, Syrbe S, **Frontini R**, Kiess W, Merkenschlager A, Bertsche T. Ambulatory care of children treated with anticonvulsants - pitfalls after discharge from hospital. Klin Padiatr. 2013;225(5):277-82.
* **Frontini R**, Miharija-Gala T, Sykora J. EAHP Survey 2010 on hospital pharmacy in Europe: part 6. Education and research. Eur J Hosp Pharm. 2013;20: 253-256.
* **Frontini R**, Miharija-Gala T, Sykora J. EAHP Survey 2010 on hospital pharmacy in Europe: parts 4 and 5. Clinical services and patient safety. Eur J Hosp Pharm. 2013;20:69-73.
* Schneider R, Ranft D, Heinitz K, Uhlmann D, Hauss J, **Frontini R**, Leinung S. Pharmaceutical care in a visceral surgical ward. Zentralbl Chir. 2012 Apr;137(2):173-9.
* **Frontini R**, Miharija-Gala T, Sykora J. EAHP Survey 2010 on hospital pharmacy in Europe: part 3. Production and quality assurance. Eur J Hosp Pharm. 2012;19:510-513.
* **Frontini R**, Miharija-Gala T, Sykora J. EAHP Survey 2010 on hospital pharmacy in Europe: part 2. Procurement and distribution. Eur J Hosp Pharm. 2012;19:460-463.
* **Frontini R**, Miharija-Gala T, Sykora J. EAHP Survey 2010 on hospital pharmacy in Europe: part 1. General frame and staffing, European Journal of Hospital Pharmacy, 2012;19:385-387.
* **Frontini R** More harm than good? Problems surrounding the regulation of prescription medication in Europe. Public Service Review Europe Union, 2010;20:139-140
* Remane Y, Schwulera U, **Frontini R**. Planung eines GMP-Bereichs in einer Krankenhausapotheke. Krankenhauspharmazie 2008;29:128–33
* Schäfer K, **Frontini R**, Nieber K. Wie hoch ist die Datenqualität der Arzneimittelanamnese? Ergebnisbericht einer Patientenbefragung zur Haus- und Klinikmedikation. Krankenhauspharmazie 2007; 28: 43-46.
* Engel A, **Frontini R**. Modulare Versorgung mit Arzneimitteln. Krankenhauspharmazie, 2006;27(1): 17–23.
* **Frontini R**. Wirksamkeit, Effektivität und Effizienz. Wie relevant sind die Ergebnisse von Studien für die klinische Praxis? Krankenhauspharmazie, 2004;25(1):1-7.
* **Frontini R**, Vogel J. Das AXON-Bilderkennungssystem. Krankenhauspharmazie, 2003;24(2): 50-53.
* **Frontini R**. Thromboseprophylaxe und Pharmakoökonomie. PantaRei 2001;1:14-15.
* **Frontini R**, Seitz HJ. Qualitätsmanagement, Arzneimitteleinsatz und Pharmakoökonomie. Erfahrungen mit dem Programm RaTh©. Krankenhauspharmazie 2001; 22(2): 69-72.
* **Frontini R**. Evidenz Basierte Medizin als Grundlage einer pharmakoökonomischen Evaluation. Krankenhauspharmazie, 2000; 21(5): 213-217.
* **Frontini R**, Mielck JB. Interactions between bendroflumethiazide and water soluble polymers. II. Factors promoting drug-polymer association. Eur. J. Pharm. Biopharm.1997;43:309-314.
* **Frontini R**, Mielck JB. Interactions between bendroflumethiazide and water soluble polymers. I. Solubility of bendroflumethiazide in water from solid dispersions and formation of associates under climatic stress. Eur. J. Pharm. Biopharm.1997;43:185-191.
* **Frontini R**, Mielck JB. Interactions between bendroflumethiazide and water soluble polymers. III. Chemical degradation. Eur. J. Pharm. Biopharm.1997;43:85-88.
* **Frontini R**, Mielck JB. Formation of formaldehyde in polyethylenglycol and poloxamer under stress conditions. Int. J. Pharm. 1995;114:121-123.
* **Frontini R**, Mielck JB. Determination and quantitation of bendroflumethiazide and its degradation products using HPLC. J.Liq.Chromat. 1992;15(14): 2519-2528.